Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AN2 Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform. Its disclosures cover common stock registration, operating and financial results, clinical and regulatory updates, risk factors and material events related to its development pipeline.
ANTX filings also include proxy materials for director elections and auditor ratification, 8-K reports on material agreements, equity and warrant financing arrangements, at-the-market sale agreements, equity incentive plan matters, option repricing, officer appointments, governance changes and capital-structure disclosures.
Aziz Kabeer reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics, Inc. director Aziz Kabeer received a grant of 2,852 shares of common stock on July 10, 2026 as compensation under the non-employee director compensation policy, in lieu of cash, with all shares vesting immediately. Following this award, he holds 59,106 shares directly. Additional indirect holdings of 377,542 and 1,995,958 shares are held through Adjuvant Global Health Technology Fund entities, where he may be deemed to share voting and dispositive power but each related person and entity disclaims beneficial ownership except to the extent of pecuniary interest.
Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics, Inc. director Gilbert Lynn Marks received a grant of 2,789 shares of Common Stock on July 10, 2026. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and vest immediately. Following this award, Marks directly holds 81,873 shares of Common Stock.
Martin Patricia A. reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics, Inc. director Patricia A. Martin received a grant of 766 shares of Common Stock on July 10, 2026. The shares were issued in lieu of cash fees under the company’s non-employee director compensation policy and vest immediately, bringing her direct holdings to 18,863 shares.
AN2 Therapeutics, Inc. officer Joshua M. Eizen reported an open-market sale of 5,945 shares of common stock at $4.172 per share on July 8, 2026. A footnote explains these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units on July 1, 2026, indicating this was a tax-related disposition rather than a discretionary sale. After the transaction, Eizen held 206,554 shares directly, and this balance reflects the prior purchase of 5,000 shares under the 2022 Employee Stock Purchase Plan on March 31, 2026. The reported holdings also include unvested RSUs scheduled to vest annually over four years from various grant dates in 2024–2026, subject to continued service.
AN2 Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders. A quorum was present, with 22,741,535 shares represented, equal to 63.18% of the 35,995,545 shares outstanding as of April 15, 2026.
Stockholders elected Class I directors Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., to serve until the 2029 annual meeting or until their successors are chosen. Support ranged from 13,547,536 to 15,947,854 votes for, with broker non-votes of 5,235,125 on each nominee.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 22,724,674 votes for, 13 votes against, and 16,848 abstentions.
AN2 Therapeutics reported positive early-stage data for its oral CPSF3 inhibitor AN2-502998 targeting chronic Chagas disease. A 28-day nonhuman primate study showed parasite elimination at exposures planned for humans, and a Phase 1 first-in-human trial in healthy volunteers found a favorable safety and tolerability profile with no dose-limiting toxicities. The company plans to advance AN2-502998 into a Phase 2 proof-of-concept study in collaboration with DNDi and highlights that Chagas disease affects over 300,000 people in the U.S. and about 10 million globally, with no FDA-approved treatments for adults. AN2 also notes that, if approved, AN2-502998 could qualify for an FDA Tropical Disease Priority Review Voucher and views Chagas disease as a potential multi-billion-dollar global market.
AN2 Therapeutics, Inc. Principal Accounting Officer Sarah Joanne Williams reported a small sale of 265 shares of common stock at $4.43 per share. According to the footnotes, these shares were sold under the grant terms to satisfy tax withholding obligations from Restricted Stock Units that vested on May 29, 2026, making this a routine tax-related transaction rather than a discretionary sale.
After this sale, Williams directly holds 66,583 shares of common stock. She also has unvested RSUs, including 48,375 RSUs vesting over four years from January 1, 2026, 10,938 RSUs vesting over four years from January 1, 2025, and 11,850 RSUs vesting quarterly over four years from May 28, 2024, all subject to continued service. The footnotes note that, from the RSUs under the latter two awards, 3,766 shares have been sold to cover taxes and 814 shares have been sold on the open market.
AN2 Therapeutics ownership disclosure: an amendment shows Almitas Capital LLC beneficially owns 1,479,129 shares of common stock, representing 4.1% of the class. The filing lists sole voting and sole dispositive power over 1,479,129 shares. The filing is signed by Ronald Mass as Managing Principal on 05/15/2026.
AN2 Therapeutics reported a Q1 2026 net loss of $10.0M, slightly improved from $10.6M a year earlier, as operating expenses declined modestly. Research and development was $6.7M, reflecting its focus on advancing a boron-chemistry small-molecule pipeline across hematologic, infectious disease, and oncology indications.
Cash, cash equivalents and investments totaled $85.3M as of March 31, 2026, boosted by a March 2026 private placement that raised roughly $40.0M in gross proceeds through common stock and pre-funded warrants. Management believes this cash will fund the current operating plan for at least twelve months.
Clinically, AN2 plans a Phase 2 proof-of-concept study of epetraborole in polycythemia vera starting in Q3 2026, supports an investigator-initiated trial in M. abscessus lung disease with topline data expected in late 2027, and has completed Phase 1 dosing of AN2-502998 for chronic Chagas disease ahead of Phase 1/NHP data in Q2 2026 and a planned Phase 2 later in 2026. The company also declared an ENPP1 oncology candidate and continues discussions with U.S. agencies to fund Phase 2 development of epetraborole for acute melioidosis.
AN2 Therapeutics reported first quarter 2026 results showing a net loss of $10.0 million, slightly improved from $10.6 million a year earlier, as research and development spending declined to $6.7 million while general and administrative costs held steady at $3.8 million.
Cash, cash equivalents and investments totaled $85.3 million at March 31, 2026, supported by $40.0 million of gross proceeds from a March private placement, which the company expects will fund operations into 2029. AN2 highlighted progress across its boron chemistry pipeline, including plans to move oral epetraborole into Phase 2 for polycythemia vera, an investigator-initiated Phase 2 trial in M. abscessus lung disease, upcoming Phase 1 and non-human primate data for AN2-502998 in chronic Chagas disease, and declaration of an ENPP1 candidate for solid tumors.